Phio Pharmaceuticals CORP

Phio Pharmaceuticals Corp. announced the appointment of Dr. R. Todd Plott, a dermatologist with extensive research and FDA experience, to its Board of Directors.

Phio Pharmaceuticals announced first quarter 2026 financial results, highlighting the completion of its PH-762 Phase 1b skin cancer trial and securing development agreements.

Phio Pharmaceuticals Corp. has entered into an At The Market Offering Agreement to sell up to $6.36 million in common stock.

Phio Pharmaceuticals signed a U.S. cGMP manufacturing agreement to produce PH-762 for clinical and potential commercial use, citing favorable Phase 1b signals and runway into H1 2027.

Phio Pharmaceuticals reports favorable Phase 1b data for lead cancer drug PH-762 and secures $23.7 million, extending cash runway into 2027.

Phio Pharmaceuticals announced positive safety and pathological response results from its Phase 1b clinical trial of PH-762 for skin cancer, with high response rates in the final dose cohort.

Phio Pharmaceuticals Corp. reports increased cash reserves and progress in its PH-762 clinical trial, bolstered by recent financing activities, while deferring its PH-894 program.

Phio Pharmaceuticals Corp. reported a net loss of $2.17 million for Q2 2025, while advancing its lead cancer therapeutic PH-762 in clinical trials and securing significant capital.

Phio Pharmaceuticals reports its Q1 2025 financial results and provides an update on its ongoing clinical trial for PH-762.

Phio Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in its PH-762 clinical trial and the impact of cost rationalization efforts.

Phio Pharmaceuticals reported its Q2 2024 financial results, highlighting cost rationalization efforts and progress in its PH-762 clinical trial.

Phio Pharmaceuticals reported a net loss of $2.154 million for the first quarter of 2024, as it continues to advance its clinical programs and streamline operations.

Phio Pharmaceuticals reports promising early clinical data for PH-762 and significant capital raises in 2025, extending its operational runway.

Phio Pharmaceuticals Corp. files its 10-K report for the fiscal year ended December 31, 2024, detailing financial results and progress in its clinical-stage immuno-oncology programs, particularly the Phase 1b trial of PH-762.

Phio Pharmaceuticals Corp.'s 10-K filing outlines the company's share structure, voting rights, and anti-takeover provisions, while also detailing recent financial activities and strategic shifts.

Robert J. Bitterman, Director and CEO of Phio Pharmaceuticals Corp., acquired 10,000 shares of common stock on June 26, 2026.

Phio Pharmaceuticals Director Curtis Lockshin was granted 16,600 restricted stock units, vesting on the first anniversary of the grant.

Phio Pharmaceuticals Director Jonathan Freeman acquired 16,600 shares of common stock in the form of restricted stock units, increasing his beneficial ownership to 32,655 shares.

Phio Pharmaceuticals Corp. Director David H. Deming was granted 23,800 restricted stock units, vesting in one year.

Phio Pharmaceuticals Corp.'s Chief Financial Officer, Lisa Cabott Carson, was granted 47,000 restricted stock units, vesting on the first anniversary of the grant date.

Phio Pharmaceuticals Corp. Director Patricia A. Bradford acquired 18,500 shares of common stock through the vesting of restricted stock units.

Phio Pharmaceuticals Corp. issued a proxy supplement to correct a scrivener's error regarding the total number of shares reserved for its Long Term Incentive Plan.

Phio Pharmaceuticals Corp. announced its 2025 Annual Stockholder Meeting to be held virtually on September 11, 2025, to vote on director elections, auditor ratification, an increase in the long-term incentive plan shares, and executive compensation.

Phio Pharmaceuticals Corp. is seeking shareholder approval for key corporate governance matters, including the election of directors and a significant increase in its equity incentive plan, while facing a 'going concern' warning from its auditors.

Phio Pharmaceuticals Corp. will hold its annual stockholder meeting on June 17, 2024, to vote on director elections, auditor ratification, a potential reverse stock split, and an amendment to the long-term incentive plan.

Phio Pharmaceuticals is asking stockholders to vote on proposals including a reverse stock split to maintain Nasdaq listing and an increase in shares available under its long-term incentive plan.

Phio Pharmaceuticals is registering for resale up to 5.9 million shares of common stock, primarily related to warrants issued in recent private placements.

Phio Pharmaceuticals has filed a registration statement for the resale of up to 1,131,468 shares of common stock by selling stockholders, primarily related to warrant exercises.

Phio Pharmaceuticals aims to raise up to $100 million through a shelf registration, offering various securities to fund clinical development and corporate activities.

CVI Investments and Heights Capital Management have jointly reported a 9.9% beneficial ownership stake in Phio Pharmaceuticals Corp., primarily through warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.1% beneficial ownership stake in Phio Pharmaceuticals Corp. as of December 31, 2025.

Orca Capital AG has filed an Amendment No. 5 to Schedule 13G, reporting a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp. as of December 8, 2025.

Orca Capital AG has reported a 6.5% beneficial ownership stake in Phio Pharmaceuticals Corp., holding 700,421 shares of common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp. as of November 7, 2025.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 9.9% beneficial ownership stake in Phio Pharmaceuticals Corp. common stock.